- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06047561
The Scottish Aortic Stenosis LongiTudinal Imaging and biomarkeR (SALTIRE) Programme (SALTIRE)
The goal of this observational study is to understand the processes of what causes and accelerates the disease progress in aortic stenosis and following aortic valve replacement.
Participants will undergo transthoracic echocardiography every 6 months, with annual visits for state-of-the-art scanning techniques including positron-emission tomography combined with computed tomography or magnetic resonance imaging with radiotracers designed to look at disease processes including fibrosis, calcification, inflammation and thrombosis activity.
Study Overview
Detailed Description
This will be an observational cohort study using existing and prospectively recruited cohorts for both cross-sectional and longitudinal comparison across the spectrum of aortic stenosis severity. For existing cohorts of patients who have previously undergone research assessments, we will invite them for repeated assessments.
Participants will be reviewed every 6 months in the Clinical Research Facility (CRF) over a 4-year period. They will undergo clinical assessment, blood sampling, transthoracic echocardiography and advanced imaging annually including CT angiography, magnetic resonance and positron emission tomography (PET).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Neil Craig
- Phone Number: 07383558066
- Email: neil.craig@ed.ac.uk
Study Contact Backup
- Name: David Newby
- Email: d.e.newby@ed.ac.uk
Study Locations
-
-
-
Edinburgh, United Kingdom, EH16 4SB
- Recruiting
- University of Edinburgh
-
Contact:
- Neil Craig
- Phone Number: 07383558066
- Email: neil.craig@ed.ac.uk
-
Principal Investigator:
- Neil Craig
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female aged >50 years
- Provision of informed consent prior to any study specific procedures
- Patients with bioprosthetic aortic valve replacements, including both surgically and transcatheter implanted valves
- Patients with severe aortic stenosis (peak velocity >4.0 m/s; previously recruited patients)
- Patients with moderate aortic stenosis (peak velocity 3.0-4.0 m/s; new prospectively recruited patients)
- Patients with mild aortic stenosis (peak velocity 2.5-2.9 m/s; new prospectively recruited patients)
- Patients with aortic sclerosis (tri-leaflet thickened aortic valve with no obstruction of ventricular outflow)
- Age and sex-matched healthy volunteers
Exclusion Criteria:
- Inability or unwilling to give informed consent.
- Those with an allergy to iodinated contrast
- Patients with impaired renal function (eGFR of <30 mL/min/1.73m2)
- Women who are pregnant or breastfeeding.
- Patients with known Rheumatic Heart Disease
- Patients with known Ochronosis
- Patients with known Familial Homozygous Hypercholesterolaemia
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Aortic Stenosis
Participants with Aortic Stenosis across the spectrum of disease severity
|
PET combined with CT or MRI
Other Names:
|
Aortic Valve Replacement
Participants who have previously undergone aortic valve replacement
|
PET combined with CT or MRI
Other Names:
|
Healthy Volunteers
Healthy Volunteers for the purposes of case-control analysis
|
PET combined with CT or MRI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Haemodynamic aortic valve disease progression.
Time Frame: 4 years
|
Rate of change of maximal aortic valve jet velocity (AV Vmax)
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Inflammatory, thrombotic, fibrotic and calcific aortic valve disease progression.
Time Frame: 4 years
|
Rate of change of tissue-to-background ratio (TBRmax) of FDG, GP1, FAPI and NaF PET.
|
4 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC22131
- RG/F/22/110093 (Other Grant/Funding Number: British Heart Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Assistance Publique - Hôpitaux de ParisAction Research Group; Bristol-Meyers Squibb & PfizerCompletedSymptomatic Aortic Stenosis | Eligible for Transcatheter Aortic Valve ReplacementFrance, Germany, Italy, Spain
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
Clinical Trials on PET-CT
-
Peter MacCallum Cancer Centre, AustraliaMelbourne Health; Westmead Hospital; Victorian Infectious Diseases Reference...CompletedAcute Myeloid Leukemia | Febrile Neutropenia | Acute Lymphoblastic Leukemia | Haematopoietic Stem Cell Transplant, Autologous | Haematopoietic Stem Cell Transplant, AllogeneicAustralia
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States
-
HALO DiagnosticsCompletedProstate CancerUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI)Completed
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm of Breast TNM Staging Distant Metastasis (M) | Untreated Bone MetastasesUnited States
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
The Catholic University of KoreaUnknownNon-small Cell Lung CancerKorea, Republic of
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruitingClear Cell Renal Cell CarcinomaChina